Physician
Christopher K Mocek MD PA
Christopher K Mocek MD PA was paid $29K by Medicaid between Jan 2018 and Nov 2024, across 20 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 71% of everything it billed.
33Billing provider infoCHRISTOPHER K MOCEK MD PA
LITTLE ROCK, AR 72205
LITTLE ROCK, AR 72205
33aNPI1255799656assigned 02/01/2016
33bProvider typeAnesthesiology Physician
28Total paid$29K
24GClaims9,068
24DCodes billed20
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Anesthesiology Physician providers in Arkansas
Rank by total paid#19 of 38
Median peer was paid$28K
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,079 | $13K | |
| 2019 | 957 | $9K | |
| 2020 | 944 | $4K | |
| 2021 | 3,086 | $3K | |
| 2022 | 2,306 | $250.37 | |
| 2023 | 470 | $461.38 | |
| 2024incomplete | 226 | $180.01 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 71% | 3,243 | 2,960 | $21K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 17% | 577 | 545 | $5K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 6.7% | 292 | 291 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.6% | 469 | 463 | $1K |
| G8482 | Influenza immunization administered or previously received | <1% | 261 | 251 | $0.01 |
| 3288F | <1% | 640 | 607 | $0.01 | |
| 1124F | <1% | 364 | 350 | $0.01 | |
| 4040F | <1% | 341 | 327 | $0.01 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | <1% | 335 | 317 | $0.01 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 607 | 588 | $0.01 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | <1% | 340 | 325 | $0.01 |
| G8484 | Influenza immunization was not administered, reason not given | 0% | 301 | 290 | $0.00 |
8 more codes
| G9744 | Patient not eligible due to active diagnosis of hypertension | 0% | 172 | $0.00 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 69 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 77 | $0.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 468 | $0.00 |
| 1123F | 0% | 224 | $0.00 | |
| 1036F | 0% | 170 | $0.00 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 77 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOCEK, CHRISTOPHER (OWNER)